AI Article Synopsis
- - Pancreatic acinar cell carcinoma (PACC) is a rare cancer that doesn't have its own specific treatment, so therapies are adapted from those used for pancreatic ductal adenocarcinoma (PDAC).
- - The case study discusses an older patient with recurrent PACC who achieved long-term survival through systemic chemotherapy, chemoradiotherapy, and maintenance therapy guided by a pathogenic BRCA2 variant.
- - The study highlights that BRCA variants are more common in PACC patients compared to those with PDAC, affecting treatment decisions and outcomes, and emphasizes the importance of early genomic testing in PACC treatment.
Article Abstract
Pancreatic acinar cell carcinoma (PACC) is a rare cancer with no specific treatment. The treatment and chemotherapy for PACC are selected according to pancreatic ductal adenocarcinoma (PDAC). Herein, we describe a recurrent PACC case of an older adult patient. The patient was treated with systemic chemotherapy, chemoradiotherapy, and maintenance therapy based on the pathologic germline BRCA2 variant, resulting in long-term survival. The pathogenic BRCA variant is detected more frequently in patients with PACC than in those with PDAC. The BRCA variant significantly impacts treatment selection and prognosis; therefore, early genomic analysis is recommended when treating PACC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12328-024-01981-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!